Details of the Drug

General Information of Drug (ID: DMMU6BJ)

Drug Name
Sodium bicarbonate
Synonyms
Acidosan; Colovage; Glycoprep; Golytely; Jusonin; Meylon; Natriumhydrogenkarbonat; Natron; Neut; Nulytely; Soludal; BSS plus; Baking soda; Bicarbonate of soda; Carbonic acid monosodium salt; Gripe water; Lithium bicarbonate; Monosodium hydrogen carbonate; Natrii hydrogencarbonas; Natrium bicarbonicum; Natrium hydrogencarbonicum; Natrum bicarbonicum; Sandoz sodium bicarbonate; Sel De vichy; Soda Mint; Sodium acid carbonate; Sodium bicarbonate in plastic container; Sodium bicarbonate liquid concentrate; Sodium bicarbonate solution; Sodium hydrocarbonate; Sodium hydrogen carbonate; Sodium hydrogencarbonate; NaHCO3; Bicarbonate, Sodium; Carbonic acid, monosodium salt; Co-lav; Col-evac; Go-evac; Hema BP-38; Hydrogen Carbonate, Sodium; Meylon (TN); Neut (TN); Peg-lyte; Soda (van); Soda, Baking; Sodium bicarbonate [USAN:JAN]; Carbonic acid sodium salt (1:1); E-Z-EM Prep Lyte; Sodium bicarbonate (1:1); Sodium bicarbonate (JP15/USP); Sodium carbonate (Na(HCO3)); 800 Sodium Bicarbonate Powder
Indication
Disease Entry ICD 11 Status REF
Metabolic acidosis 5C73 Approved [1], [2], [3]
Therapeutic Class
Antidiarrheals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 84.007
Topological Polar Surface Area Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 3
Chemical Identifiers
Formula
CHNaO3
IUPAC Name
sodium;hydrogen carbonate
Canonical SMILES
C(=O)(O)[O-].[Na+]
InChI
InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1
InChIKey
UIIMBOGNXHQVGW-UHFFFAOYSA-M
Cross-matching ID
PubChem CID
516892
ChEBI ID
CHEBI:32139
CAS Number
144-55-8
DrugBank ID
DB01390
TTD ID
D02FLB
VARIDT ID
DR00038
ACDINA ID
D00629

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) TTZPWGN CAC1H_HUMAN Blocker [4]
Voltage-gated potassium channel Kv4.3 (KCND3) TTPLQO0 KCND3_HUMAN Blocker [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Electroneutral sodium bicarbonate exchanger 1 (SLC4A8) DTW40Z7 S4A8_HUMAN Substrate [6]
Sodium-driven chloride bicarbonate exchanger (SLC4A10) DT7RYVF S4A10_HUMAN Substrate [7]
Anion exchange protein 4 (SLC4A9) DTSQY0W B3A4_HUMAN Substrate [8]
Sodium bicarbonate cotransporter 3 (SLC4A7) DT03V27 S4A7_HUMAN Substrate [6]
Electrogenic sodium bicarbonate cotransporter 4 (SLC4A5) DTCL4P8 S4A5_HUMAN Substrate [6]
Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4) DTWDEIL S4A4_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Metabolic acidosis
ICD Disease Classification 5C73
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DTT CACNA1H 1.31E-04 -0.76 -2.12
Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4) DTP NBCe1 3.17E-01 -1.76E-01 -2.01E-01
Electroneutral sodium bicarbonate exchanger 1 (SLC4A8) DTP NDCBE 1.00E-01 -3.40E-01 -4.11E-01
Anion exchange protein 4 (SLC4A9) DTP AE4 2.54E-01 -2.66E-02 -1.13E-01
Electrogenic sodium bicarbonate cotransporter 4 (SLC4A5) DTP NBCe2 8.63E-01 -6.11E-02 -5.24E-01
Sodium-driven chloride bicarbonate exchanger (SLC4A10) DTP NCBE 1.67E-01 -1.44E-01 -9.30E-01
Sodium bicarbonate cotransporter 3 (SLC4A7) DTP NBC3 4.23E-03 5.04E-01 1.46E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sodium bicarbonate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [20]
Bacampicillin DMP54C7 Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [20]
Vismodegib DM5IXKQ Minor Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [21]
Pexidartinib DMS2J0Z Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [22]
HKI-272 DM6QOVN Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [23]
Bosutinib DMTI8YE Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [24]
Digitoxin DMWVIGP Minor Decreased absorption of Sodium bicarbonate due to formation of complexes caused by Digitoxin. Heart failure [BD10-BD1Z] [25]
GS-5885 DMSL3DX Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by GS-5885. Hepatitis virus infection [1E50-1E51] [26]
Dolutegravir DMCZGRE Major Decreased absorption of Sodium bicarbonate due to formation of complexes caused by Dolutegravir. Human immunodeficiency virus disease [1C60-1C62] [27]
Rilpivirine DMJ0QOW Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [28]
GSK1265744 DMT8J0I Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by GSK1265744. Human immunodeficiency virus disease [1C60-1C62] [29]
Tolvaptan DMIWFRL Moderate Increased risk of hypernatremia by the combination of Sodium bicarbonate and Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [24]
Quazepam DMY4D87 Minor Altered absorption of Sodium bicarbonate due to GI dynamics variation caused by Quazepam. Insomnia [7A00-7A0Z] [30]
Ceritinib DMB920Z Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [31]
Selpercatinib DMZR15V Major Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [32]
Acalabrutinib DM7GCVW Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [33]
Ponatinib DMYGJQO Minor Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [21]
Dabrafenib DMX6OE3 Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Dabrafenib. Melanoma [2C30] [21]
Nilotinib DM7HXWT Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Nilotinib. Myeloproliferative neoplasm [2A20] [21]
Dextroamphetamine DMMIHVP Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Sodium bicarbonate caused by Dextroamphetamine mediated altered urine pH. Narcolepsy [7A20] [34]
Methamphetamine DMPM4SK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Sodium bicarbonate caused by Methamphetamine mediated altered urine pH. Pain [MG30-MG3Z] [34]
Choline salicylate DM8P137 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Sodium bicarbonate caused by Choline salicylate mediated altered urine pH. Postoperative inflammation [1A00-CA43] [35]
Riociguat DMXBLMP Moderate Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Riociguat. Pulmonary hypertension [BB01] [36]
Axitinib DMGVH6N Minor Decreased absorption of Sodium bicarbonate due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [37]
Salsalate DM13P4C Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Sodium bicarbonate caused by Salsalate mediated altered urine pH. Rheumatoid arthritis [FA20] [35]
⏷ Show the Full List of 25 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sodium bicarbonate 325 mg tablet 325 mg Oral Tablet Oral
Sodium bicarbonate 650 mg tablet 650 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4507).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018509.
4 Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
5 Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23.
6 The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
7 Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90.
8 A novel sodium bicarbonate cotransporter-like gene in an ancient duplicated region: SLC4A9 at 5q31. Genome Biol. 2001;2(4):RESEARCH0011.
9 The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem. 2010 Aug 6;285(32):24432-8.
10 Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
11 Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
12 Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
13 Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
14 Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
15 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
16 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
17 Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
18 Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020444)
20 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
21 Cerner Multum, Inc. "Australian Product Information.".
22 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23 Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
24 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25 Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30. [PMID: 7012189]
26 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
27 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
28 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
29 Cerner Multum, Inc. "Canadian Product Information.".
30 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
31 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
32 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
33 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34 Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
35 Balali-Mood M, Prescott LF "Failure of alkaline diuresis to enhance diflunisal elimination." Br J Clin Pharmacol 10 (1980): 163-5. [PMID: 7426277]
36 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
37 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.